Brannon et al. performed deep coverage, targeted next-generation sequencing in 69 matched primary and metastatic tumors and detected a concordance rate of 100% for KRAS mutation status in patients with colorectal cancer [35]. The gene discussed is KRAS; the disease is metastatic neoplasm.